SAN DIEGO, Oct. 23, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. Nall will present a corporate overview at the Dawson James Securities 4th Annual Small Cap Growth Conference on October 30, 2018 at 9:30 a.m. Eastern time (6:30 a.m. Pacific time). The conference is being held in Jupiter, Fla.
A live webcast of the corporate presentation will be available on the Company's website at ir.biocept.com. A replay of the presentation will be available for 90 days.
About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.
Investor Contact: | Media Contact: |
LHA Investor Relations | Trevelino/Keller |
Jody Cain | Colleen Murphy |
310-691-7100 | 404-214-0722, Ext. 109 |
SOURCE Biocept, Inc.
